

# FDA Indications

## Daklinza™ (Daclatasvir) + Sovaldi® (Sofosbuvir) for Genotype 3\*

See Decision Trees for  
Treatment Forms

Patient Population	Medications	Duration
Patients without cirrhosis	Daklinza + Sofosbuvir	12 weeks
Compensated (Child-Pugh A) or Decompensated (Child-Pugh B or C) cirrhosis	Daklinza + Sofosbuvir + Ribavirin	12 weeks
Post-Liver Transplant	Daklinza + Sofosbuvir + Ribavirin	12 weeks

**\*Preliminary data suggest that NS5A Genotype 3 RAV testing is recommended for all genotype 3 patients prior to treatment. Consult Liver Disease Specialist first.**